Antibody Discovery Market Analysis, Growth, Size, Share - 2030
ومن المتوقع أن يرتفع حجم سوق اكتشاف الأجسام المضادة من 2.94 مليار دولار أمريكي في عام 2022 إلى 4.92 مليار دولار أمريكي بحلول عام 2030؛ من المتوقع أن ينمو السوق بمعدل نمو سنوي مركب قدره 6.7٪ خلال الفترة 2022-2030.CAGR of 6.7% during 2022–2030.
وجهة نظر المحلل:
يتضمن التقرير آفاق النمو بسبب اتجاهات سوق اكتشاف الأجسام المضادة الحالية وتأثيرها المتوقع خلال الفترة المتوقعة. عوامل مثل تزايد انتشار الأمراض المزمنة في جميع أنحاء العالم وزيادة الطلب على الطب الشخصي تغذي نمو سوق اكتشاف أدوية الأجسام المضادة. يتعرض كبار السن لخطر كبير للإصابة بالأمراض المزمنة مثل السرطان وأمراض المناعة الذاتية والأمراض المعدية، مما يعكس الحاجة إلى المواد البيولوجية والأدوية للعلاج.biologics and drugs for treatment.
بالإضافة إلى ذلك، هناك تركيز متزايد على تطوير أجسام مضادة أكثر أمانًا. على سبيل المثال، هوميرا هو جسم مضاد متوافق مع البشر ومن غير المرجح أن يسبب آثارًا جانبية مقارنة بالأجسام المضادة التقليدية للفئران. ومن المتوقع أن تصبح هذه الأجسام المضادة الأكثر أمانًا أكثر شيوعًا مع التركيز المتزايد على سلامة الأدوية. ومع ذلك، فإن نمو سوق اكتشاف الأجسام المضادة محدود بسبب السياسات التنظيمية الصارمة والطلب المتزايد على الأدوية البديلة مثل العلاج الجيني والأدوية الجزيئية الصغيرة. بالإضافة إلى ذلك، فإن التقدم التكنولوجي مثل عرض العاثيات، والفحص عالي الإنتاجية، والمعلوماتية الحيوية يسهل اكتشاف وتطوير أجسام مضادة جديدة. وينتج عن ذلك عملية تطوير أدوية أكثر كفاءة وفعالية من حيث التكلفة ويخلق فرص نمو مربحة للسوق.Humira is a humanized antibody that is less likely to cause side effects than traditional mouse antibodies. Such safer bioinformatics are facilitating the discovery and development of new antibodies. This results in a more efficient and cost-effective drug development process and creates lucrative growth opportunities for the market.
نظرة عامة على السوق:
يؤدي التوسع في صناعة الأدوية الحيوية ، والتي تركز بشكل كبير على المواد البيولوجية، إلى زيادة الطلب على خدمات أبحاث الأجسام المضادة أكثر من ذي قبل. تعمل زيادة التعاون بين الجهات الفاعلة في الصناعة والمؤسسات الأكاديمية على تسهيل مشاركة الموارد وتسريع اكتشاف الأجسام المضادة. إن التحول نحو تطوير الأدوية التي تركز على المريض، مع التركيز على الطب الشخصي وتفضيلات المريض، يعزز سوق اكتشاف الأجسام المضادة.
أدى التقدم التكنولوجي المستمر مثل الفحص عالي الإنتاجية وعرض العاثيات وتسلسل الجيل التالي إلى تحسين كفاءة وسرعة عمليات اكتشاف الأجسام المضادة. كما أن زيادة التمويل لأنشطة البحث والتطوير من المنظمات الحكومية والشركات الخاصة يحفز أيضًا مبادرات اكتشاف الأجسام المضادة. تكتسب الأجسام المضادة وحيدة النسيلة شعبية في التطبيقات العلاجية بسبب خصوصيتها وفعاليتها في استهداف مستضدات محددة، مما يؤدي إلى زيادة الطلب على خدمات أبحاث الأجسام المضادة. لذلك، من المرجح أن يكون للطلب المتزايد على العلاجات القائمة على الأجسام المضادة وتفضيل الاستعانة بمصادر خارجية تأثير كبير على توقعات سوق اكتشاف الأجسام المضادة في السنوات القليلة المقبلة.marketforecast in the next few years.
تخصيص البحث ليناسب متطلباتك
يمكننا تحسين وتخصيص التحليل والنطاق الذي لم يتم تلبيته من خلال عروضنا القياسية. ستساعدك هذه المرونة في الحصول على المعلومات الدقيقة اللازمة لتخطيط أعمالك واتخاذ القرارات.
سوق اكتشاف الأجسام المضادة:
معدل النمو السنوي المركب (2022 - 2030)6.7%- حجم السوق 2022
2.94 مليار دولار أمريكي - حجم السوق 2030
4.92 مليار دولار أمريكي
ديناميات السوق
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
اللاعبين الرئيسيين
- المختبرات الحيوية الإبداعية
- إيفوتيك
- بيودورو-سونديا
- تحليل بروكر الخلوي
- مولد حيوي
- مختبرات نهر تشارلز
- اراجين علوم الحياة الجندي. المحدودة
- تويست العلوم البيولوجية
- نانو سيليكت الطبية الحيوية
نظرة عامة إقليمية
- أمريكا الشمالية
- أوروبا
- آسيا والمحيط الهادئ
- أمريكا الجنوبية والوسطى
- الشرق الأوسط وأفريقيا
تجزئة السوق
نوع الجسم المضاد- الأجسام المضادة وحيدة النسيلة
- الأجسام المضادة متعددة النسيلة
- آحرون
طبيعة- إنساني وأنسنة
- خيالي
- الفئران
خدمة- عرض بالعاثية
- ورم هجين
- الحيوان المعدل وراثيا
- خلية واحدة
- عرض الخميرة
المستخدم النهائي- شركات الأدوية والتكنولوجيا الحيوية
- مختبرات البحوث
- آحرون
- يعرض نموذج PDF بنية المحتوى وطبيعة المعلومات من خلال التحليل النوعي والكمي.
سائق السوق:
زيادة الاستثمارات في البحث والتطوير تدفع نمو السوق
Antibodies, including monoclonal and polyclonal, find applications in academic, research, and pharmaceutical institutes and organizations, wherein they are used in several R&D activities related to drug and biomarker development, and other therapeutic and clinical diagnostics product development. Small and medium-sized companies focus on raising their R&D investments every year. In April 2020, the US federal government assigned US$ 3.5 billion to the Biomedical Advanced Research and Development Authority (BARDA) under its Coronavirus Aid, Relief, and Economic Security (CARES) Act to provide financial support for the manufacturing, production, and procurement of vaccines, diagnostics, therapeutics, and small molecule active pharmaceutical ingredients (APIs), among others. For example, in September 2022, Abzena (a leader in biologics and antibody-drug conjugates) announced intentions to expand its research and development capabilities in Cambridge to aid in rapid antibody discovery. Further, Bio-Rad, a pharmaceutical company, provides 10,000 antibodies, along with antigens, reagents, and buffers, to develop in vitro diagnostic tests. Therefore, the increasing investments by pharmaceutical companies in research and development activities related to antibody discovery to develop better treatment options for various diseases propels the antibody discovery market growth.
Segmental Analysis:
The antibody discovery market analysis has been carried out by considering the following segments: antibody type, nature, services, and end user.
Based on antibody type, the antibody discovery market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held the largest market share in 2022. Moreover, the same segment is anticipated to register the highest CAGR of 6.9% during 2022–2030. Monoclonal antibodies (mAbs) are designed to interact specifically with diseased cells without harming healthy cells. Cancer therapy is one of the significant application areas wherein monoclonal antibodies are used. These are widely accepted biologics and are expected to present a billion-dollar opportunity to pharmaceutical manufacturers during the forecast period. Moreover, patients and physicians are becoming increasingly aware of mAb therapy applications. As a result, the approval of blockbuster mAbs as effective treatments of various indications is expected to favor the antibody discovery market during the forecast period. Drugs such as Avastin, Herceptin, Remicade, and Rituxan have been approved by the FDA for treating cancer, rheumatoid arthritis, Crohn's disease, ulcerative colitis, etc.
The market, based on nature, is segmented into human and humanized, chimeric, and murine. The human and humanized segment held the largest antibody discovery market share in 2022, and the same segment is anticipated to register a higher CAGR during the forecast period. Human and humanized antibodies are engineered genetically by grafting complementarity-determining regions (CDRs) from a non-human antibody with the desired antigen binding specificity into the corresponding CDRs of another antibody, which is more prominently derived from humans. These antibodies are gaining significant acceptance and popularity owing to their higher specificity and stability, and lesser costs. Additionally, human and humanized antibodies have exhibited attractive clinical efficacy in clinical studies.
The antibody discovery market, based on service, is divided into phage display, hybridoma, transgenic animal, yeast display, and single cell. The phage display segment dominated the market share in 2022, and the same segment is anticipated to register the highest CAGR of 7.3% during the forecast period. The phage display technique is used for in vitro antibody selection. Viruses that infect bacteria are mainly used as gene vectors for the expression of antibody fragments (proteins), which are typically single-chain variable fragments (scFv) or Fab fragments present on the virus. The expressed antibody fragments can then be examined for binding to a specific target of interest. Speed, simplicity, and cost-effectiveness associated with the process of identification of binders are among the major advantages of phage display technology.
Based on end user, the antibody discovery market is divided into pharmaceutical and biotechnology companies, research laboratories, and others. The pharmaceutical and biotechnology companies segment held the largest antibody discovery market share in 2022, and the same segment is anticipated to register a higher CAGR of 7.2% during 2022–2030. Pharmaceutical and biotechnology companies account for a significant part of the antibody discovery process because of their capabilities to identify antibodies for any specific disease and produce them on commercial scales. The elevating demand for high-specificity antibodies for drug discovery and development; growing research in the areas of proteomics and genomics; increasing need for antibodies for identifying new targets and assays; and rising R&D activities in several therapeutic areas such as cancer, HIV/AIDS, immunodeficiency diseases, and blood disorders are the critical factors driving the demand for antibody discovery products, solutions, and services in pharmaceutical and biotechnology companies.
Regional Analysis:
The scope of the antibody discovery market report includes North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The market in North America was valued at US$ 1.29 billion in 2022 and is projected to reach US$ 2.20 billion by 2030; it is expected to register a CAGR of 6.8% during 2022–2030. The North American market is segmented into the US, Canada, and Mexico. Market growth in the region is determined by an increase in the prevalence of cancer, the strong presence of the antibody research industry, and technological advancements in the R&D sector.
According to the American Cancer Society, ~1.8 million new cancer cases were diagnosed and ~606,520 deaths related to cancer were recorded in the US in 2020. This bolsters the need for therapeutic antibodies, thereby fueling the market growth. Asia Pacific is expected to register the highest CAGR during 2022–2030. The Asia Pacific antibody discovery market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest market share in 2022, and India is expected to show a significant growth rate in the market. The biopharmaceutical industry in China is undergoing a tremendous shift, evolving from a generics-focused landscape to a thriving innovation hub. Additionally, progress in industrialization, and the application of novel drugs, high-end medical devices, and techniques contribute to the market growth in China. Further, the growing number of market players focusing on countries in Asia Pacific for their geographic expansion and other growth strategies, the rising count of research centers, and a notable increase in government funding fuel the antibody discovery market in Asia Pacific.
Antibody Discovery Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 2.94 Billion |
| Market Size by 2030 | US$ 4.92 Billion |
| Global CAGR (2022 - 2030) | 6.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered | By Antibody Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Key Player Analysis:
Creative Biolabs، Evotec، BioDuro-Sundia، Bruker Cellular Analysis، Biocytogen، Charles River Laboratories، Aragen Life Sciences Pvt. تعد شركة Ltd وTwist Bioscience وNanoCellect Biomedical وSartorius AG من بين اللاعبين الرئيسيين الذين تم ذكرهم في تقرير سوق اكتشاف الأجسام المضادة.
التطورات الأخيرة:
تتبنى الشركات العاملة في سوق اكتشاف الأجسام المضادة مبادرات استراتيجية مثل عمليات الدمج والاستحواذ والشراكات وما إلى ذلك. وفيما يلي بعض تطورات السوق الأخيرة:
- في يناير 2024، أطلقت شركة Biocytogen Pharmaceuticals Co Ltd علامة تجارية فرعية جديدة تسمى RenBiologics لتمثيل قسم أعمال اكتشاف الأجسام المضادة بالشركة. من المتوقع أن تغطي أعمال شركة RenBiologics الترخيص الخارجي/التطوير المشترك لمكتبة الشركة الواسعة من الأجسام المضادة البشرية بالكامل، بالإضافة إلى ترخيص RenMice، وهي منصة اكتشاف الأجسام المضادة البشرية بالكامل/TCR الخاصة بشركة Biocytogen Pharmaceuticals.
- في ديسمبر 2023، أعلنت شركة Biocytogen Pharmaceuticals Co Ltd عن تقييم وخيارات واتفاقية ترخيص للأجسام المضادة مع Ona Therapeutics لتصميم مستحضرات صيدلانية حيوية ضد أنواع السرطان المتقدمة. وبموجب شروط الاتفاقية، منحت شركة Biocytogen Pharmaceuticals Co Ltd شركة Ona حق الوصول لتقييم الأجسام المضادة البشرية المشتقة بالكامل من RenMice ضد هدف ورم محدد، مع خيار الترخيص الحصري لأجسام مضادة مختارة لتطوير وتصنيع وتسويق أدوية الأجسام المضادة. المترافقات (ADCs) في المؤشرات والأقاليم المتفق عليها بشكل متبادل.
- في يونيو 2022، أعلنت شركة Evotec SE عن تعاونها مع Janssen Pharmaceutica NV، إحدى شركات Johnson & Johnson لاكتشاف الأدوية. وبموجب هذا التعاون، تهدف شركة Evotec SE إلى تقييم منصات TargetAlloMod الخاصة بها لاكتشاف المرشحين العلاجيين من الدرجة الأولى مع أنماط عمل جديدة، وستقوم شركة Janssen Pharmaceutica NV بتسهيل ذلك.
- في أغسطس 2021، دخلت Sartorius AG في شراكة مع جامعة ماكماستر لتحسين عمليات تصنيع الأجسام المضادة وغيرها من العلاجات القائمة على الفيروسات لأمراض مثل كوفيد-19 والسرطان والاضطرابات الوراثية. أدت هذه الشراكة مع جامعة ماكماستر إلى أبحاث مؤثرة أتاحت علاجات مهمة على نطاق أوسع.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Charles River Laboratories and Evotec are the top two companies that hold huge market shares in the antibody discovery market.
Global antibody discovery market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The North America regional market is expected to grow with a CAGR of 6.8% during 2022–2030. Market growth in this region is attributed to the increasing prevalence of cancer, the strong presence of the antibody research industry, and technological advancements in the R&D sector help in the market expansion. An upsurge in funding further enables the development of new technologies, pooling of resources and expertise across countries and organizations, and conducting research work into existing antibody treatments. This has led to a better understanding of the immune system, and the development of effective and targeted antibodies. Additionally, the increased funding allows scientists to conduct large-scale clinical trials that are mandatory to evaluate the effectiveness of a particular antibody. The Asia Pacific molecular spectroscopy market is expected to grow at the highest CAGR of 7.3% during 2022–2030. China is predicted to hold the largest share of the market in 2022, and India is expected to show a significant growth rate in the market. China is predicted to hold the largest market share in 2022, and India is expected to show a significant growth rate in the market. The biopharmaceutical industry in China is undergoing a tremendous shift, evolving from a generics-focused landscape to a thriving innovation hub. Additionally, progress in industrialization, and the application of novel drugs, high-end medical devices, and techniques contribute to the antibody discovery market growth in China. Further, the growing number of market players focusing on countries in Asia Pacific for their geographic expansion and other growth strategies, the rising count of research centers, and a notable increase in government funding fuel the antibody discovery market growth in Asia Pacific.
Antibody discovery, a nuanced endeavor, refers to the complicated process of discovering novel antibodies. This endeavor involves the search for antibodies that recognize and bind to specific targets, with applications extending to diagnostics and therapy. Antibody discovery methods such as phage display and hybridoma technology are widely used. Their use is essential to the search for antibodies that recognize and bind to specific targets, paving the way for applications in diagnostics and therapeutic interventions. The resulting outcome of this process plays a crucial role in developing novel drugs, vaccines, diagnostics, and various therapeutic modalities. By enabling researchers to produce antibodies tailored to recognize and target precise antigens, the scale of antibody discovery is of paramount importance.
Key factors that are driving the antibody discovery market are the increasing investments in research & development and the rising incidence of cancer.
The CAGR value of the antibody discovery market during the forecasted period of 2022-2030 is 6.7%.
The monoclonal antibodies segment held the largest share of the market in the global antibody discovery market and held the largest market share of 82.6% in 2022.
The phage display segment dominated the global antibody discovery market and held the largest market share of 35.8% in 2022.
The molecular spectroscopy market majorly consists of the players such Creative Biolabs, Evotec, BioDuro-Sundia, Bruker Cellular Analysis, Biocytogen, Charles River Laboratories, Aragen Life Sciences Pvt. Ltd, Twist Bioscience, NanoCellect Biomedical, and Sartorius AG.
The List of Companies - Antibody Discovery Market
- Creative Biolabs
- Evotec
- BioDuro-Sundia
- Bruker Cellular Analysis
- Biocytogen
- Charles River Laboratories
- Aragen Life Sciences Pvt. Ltd
- Twist Bioscience
- NanoCellect Biomedical
- Sartorius AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For